Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology, Inc. disclosure: SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M1) L.P. and SVF Endurance (Cayman) Limited report shared beneficial ownership of 10,948,093 shares of Common Stock as of March 31, 2026, representing 6.5% of the class. The statement notes 168,651,974 shares outstanding as of April 29, 2026. SVF Endurance (Cayman) Limited is the record holder, SVF is its sole owner, and SBIA UK serves as SVF's appointed AIFM and may be deemed to share beneficial ownership.
Vir Biotechnology, Inc. reported a net loss of $125.7 million for the quarter ended March 31, 2026, compared with a $121.0 million loss a year earlier, as it continued heavy investment in hepatitis delta and oncology programs. Total revenue was minimal at $(29) thousand, reflecting lower grant and collaboration activity.
Research and development spending was $108.9 million, driven by manufacturing and clinical costs for the ECLIPSE hepatitis delta program and dual-masked T-cell engagers. Cash, cash equivalents and investments totaled $809.3 million, helped by $162.3 million of net proceeds from a February follow-on equity offering. After quarter-end, Vir closed a major collaboration with Astellas around prostate cancer candidate VIR-5500, including a $240 million upfront payment and a $75 million equity investment.
Vir Biotechnology, Inc. reported a first quarter 2026 net loss of $125.7 million, or $0.85 per share, compared with a $121.0 million loss a year earlier. The company ended March 31, 2026 with $809.3 million in cash, cash equivalents and investments and completed a follow-on equity offering raising $172.5 million in gross proceeds.
Vir highlighted positive Phase 2 SOLSTICE data in chronic hepatitis delta, continued progress in its ECLIPSE registrational program, and advancement of its PRO-XTEN® dual-masked T-cell engager oncology pipeline, including the Astellas collaboration on VIR-5500 and dosing of the first patient in Phase 1 dose-expansion cohorts. Based on current plans and including expected Astellas proceeds, Vir now expects its cash resources to fund operations into the second half of 2028.
Vir Biotechnology, Inc. director Vicki L. Sato reported an open-market sale of 22,000 shares of common stock on May 1, 2026 at a weighted average price of $10.0466 per share.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025. After this transaction, she continues to hold 1,078,391 shares of Vir Biotechnology common stock directly.
Vir Biotechnology, Inc. director and President & CEO Marianne De Backer reported a restructuring of her common stock holdings. Two Form 4 transactions with code J reclassified a total of 467,064 shares at a stated price of $0.00 per share.
One entry moved 233,532 shares into indirect ownership held by the Ureel-De Backer Family Trust, where she and her spouse serve as trustees, following a transfer without consideration for tax and estate planning purposes. A parallel entry shows 233,532 shares under direct ownership, leaving her with 714,613 directly held shares and 286,650 indirectly held shares after these changes.
Issuer files a Form 144 notice relating to proposed resale of common stock. The filing lists 88,958 shares identified for sale on 04/30/2026, including option-derived lots of 65,625 and 23,333 shares. The filing also reports three open-market sales by Mark D. Eisner totaling 5,594 shares in February 2026 with proceeds shown.
Vir Biotechnology Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 9,257,235 shares of Vir Biotechnology common stock, representing 5.79% of the class. The filing shows sole dispositive power over 9,257,235 shares and sole voting power for 41,658 shares. Vanguard states these holdings reflect positions managed by Vanguard Portfolio Management LLC and affiliated business divisions, including securities held by Vanguard funds and certain client accounts. The filing is signed by a Vanguard official.
Vir Biotechnology has issued its 2026 definitive proxy for the virtual annual stockholder meeting on May 26, 2026, at 9:00 a.m. Pacific Time. Stockholders will vote on electing three Class I directors to terms ending in 2029, an advisory say-on-pay resolution on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor for 2026.
The company highlights strong governance practices, including an independent board chair, fully independent key committees and stock ownership guidelines. Its compensation program emphasizes pay-for-performance, with most executive pay at risk and tied to corporate achievements such as advancing the ECLIPSE Phase 3 program, publishing SOLSTICE Week 48 data, and progressing T-cell engager programs.
Vir Biotechnology, Inc. reported a leadership change in its medical organization. Executive Vice President and Chief Medical Officer Mark Eisner, MD, MPH has informed the company that he will step down from his role, effective April 24, 2026. The company has begun a search for a successor to oversee its clinical and medical strategy.